The EPS projection of Cardiome Pharma Corporation (NASDAQ:CRME) for quarter ended 2016-09-30 is $-0.18. A week before, the EPS forecast was $-0.18 against target of $-0.18, a month earlier. This estimate stood at $-0.18 60 days earlier versus forecast of $-0.18 90 days earlier, confirming a deviation of 0%.
Cardiome Pharma Corporation (NASDAQ:CRME) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 1, 0 and 1, respectively.
The downgrade of EPS estimates for Cardiome Pharma Corporation (NASDAQ:CRME) in the preceding 120, 60, 30 and 90 days were 1, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Cardiome Pharma Corporation (NASDAQ:CRME) was $-0.18. This projection was computed after accounting 2 calls. As reported on 2016-05-13 the EPS was $-0.06. The change was $0.12, demonstrating a percentage deviation of 66.67%. The projections confirmed a standard deviation of 0.06.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Cardiome Pharma Corporation (NASDAQ:CRME) stands at $8.41 and the median estimate at $7.72. Almost 3 analysts announced their estimates.
The highest estimate is $10.41 while the lowest target is $7.1 showing standard deviation of 1.759%.
As many as 3 analysts released sales estimates reised in upside while 3 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 3 revised sales number projection on upside while 3 lowered the sales target, demonstrating a deviation of -3.94%.
A quarter ago, 3 hiked sales estimations and 3 reduced sales forecast. Cardiome Pharma Corporation (NASDAQ:CRME) stated that the change in forecast was -1.637%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...